Analytical Data
-
Gene name
VACWR052
- Application
-
Alternative Names
(37 kDa protein)(Palmitoylated EV membrane protein)(p37K)
-
Species
Vaccinia virus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04021
-
Expression Region
1-372aa
-
Molecular Weight
49.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VACWR052 is a recombinant protein derived from the Vaccinia virus, which has garnered interest in the field of immunology and vaccine development. The Vaccinia virus, known for its use as a live vaccine against smallpox, has unique immunogenic properties that make it a valuable tool for research. The VACWR052 protein, in particular, plays a crucial role in modulating the host immune response. Studies have shown that it interacts with various components of the immune system, potentially influencing the activation and regulation of T cells and cytokine production. Understanding the molecular mechanisms of VACWR052 can provide insights into how viral proteins can enhance or inhibit immune responses, paving the way for novel therapeutic strategies and vaccine designs. Furthermore, investigations into VACWR052 may also contribute to the development of vaccines against other pathogens, leveraging the Vaccinia virus's ability to elicit strong and long-lasting immunity. As such, research on VACWR052 not only aims to elucidate its biological functions but also seeks to harness its potential in advancing vaccine technology and improving immune interventions.
